The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota
Sponsored by Peter Humaidan
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 2 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Abnormal vaginal microbiota.
- The screening swab should be repeated if more than 3 months old.
- HIV, Hepatitis B or C positivity.
- First, second or third IVF stimulation cycle or embryo transfer therefrom.
- BMI<35
- Written informed consent.
Exclusion Criteria
- Known or suspected hypersensitivity to clindamycin.
- HPV CIN 2 or higher.
- Former or current inflammatory bowel disease
- Severe concomitant disease, including diabetes.
- MAX 2 embryos may be transferred
- Artificial heart valve
- Intrauterine malformations with operation indication as determined by treating physician (Polyps, Septum, fibroma)